Early Lapatinib-Induced Skin Rash Predicts Better Survival With

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Early Adverse Events predict Survival Outcomes in HER2-positive

Lapatinib as a component of neoadjuvant therapy for HER2-positive

First-line lapatinib trials in metastatic breast cancer

Association between pertuzumab-associated diarrhoea and rash and

Cancers, Free Full-Text

Clinical practice guidelines for the prevention and treatment of

Multicenter Phase II Study of Neoadjuvant Lapatinib and

Pharmaceutics, Free Full-Text

Page 1529 – Cancer Therapy Advisor